ASX ANNOUNCEMENT

Lumos Diagnostics receives CPT PLA procedure code approval for FebriDx in the US

Key Highlights

- **FebriDx reimbursement rate of $41.38/test has been established** by the Centers for Medicare and Medicaid Services (CMS) Panel and will be published on the Clinical Lab Fee Schedule (CLFS) on January 1, 2025.
- **The FebriDx PLA code is 0442U.** Proprietary Laboratory Analyses (PLA) Codes are an addition to the Current Procedure Terminology (CPT®) code set approved by the American Medical Association (AMA) CPT® Editorial Panel.
- **Next steps:** In addition to implementing FebriDx into clinical pathways, triage workflows, and achieving CLIA waiver labelling, Lumos will now engage with US private and government payers, as well as other key stakeholders, to establish reimbursement and coverage policies.

MELBOURNE, Australia (5 December 2024) – Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") a leader in rapid, point-of-care diagnostic technologies, is pleased to announce that it has achieved a new milestone in the commercial rollout of its FebriDx point-of-care test. The Company received approval from the CMS Panel for the FebriDx PLA code (0442U) to be reimbursed at a rate of US$41.38/test. The FebriDx PLA code will be published on the Clinical Lab Fee Schedule and take effect on January 1,2025.

The PLA code, issued by the American Medical Association, will play a vital role in securing reimbursement for FebriDx from both government and private insurers. This approval is a critical step toward enhancing FebriDx's accessibility and adoption and is expected to facilitate broader use of the test over time, by making it more affordable.

FebriDx is unique in its ability to distinguish between bacterial and non-bacterial infections at the point of care. This is a critical capability, given that most acute respiratory infections stem from viruses and do not require antibiotics. Despite this, antibiotics are prescribed in up to 50% of such cases, contributing to the growing issue of antibiotic resistance. The U.S. faces significant challenges in this area, with antibiotic resistance leading to approximately 2.8 million illnesses and 35,000 deaths annually.

Doug Ward, CEO and Managing Director of Lumos Diagnostics, stated that the unique PLA code represents a further advancement in the U.S. commercialization of FebriDx. *"This reimbursement pathway is another important step towards removing barriers to access and potentially benefitting millions of Americans."*

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:
Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 (0) 423 139 163

Investor Contact:
Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598